Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,147 trials

NCT07260942
Recruiting
Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
Not applicable · France · 1 site
Registry update: 18 May 2026
NCT07830407
Recruiting
Pre-Clinical Validation of ChemoINTEL Unified Algorithm Chemotherapeutic Response Prediction in Patients With Colorectal Cancer
Not applicable · United Kingdom · 1 site
Registry update: 21 Sept 2026
NCT07425522
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Phase 1 · United States · 12 sites
Registry update: 9 Oct 2026
NCT07499232
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · Austria, Belgium, Canada, China, Czechia, Germany, Denmark, Spain, France, United Kingdom, Hungary, Italy, Netherlands, Poland, Sweden, Slovakia, United States · 164 sites
Registry update: 3 Nov 2026
NCT07467018
Recruiting
Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County
Not applicable · United States · 1 site
Registry update: 23 Apr 2026
NCT07551011
Recruiting
Impact of Behavioural Modification Working Toolkit Among Women With Gestational Diabetes Mellitus and Hypertension
Not applicable · Pakistan · 2 sites
Registry update: 13 Jul 2026
NCT07346144
Recruiting
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
Phase 1/2 · United Kingdom, United States · 2 sites
Registry update: 23 Oct 2026
2024-518898-34-00
Recruiting
A clinical study is aimed at comparing the effectiveness of two types of cell therapy in treating anal fistulas associated with Crohn's disease.
Phase 2/3 · Poland · 2 sites
Registry update: 11 Mar 2026
NCT07531095
Recruiting
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Phase 1 · Australia, Belgium, Switzerland, Germany, Spain, France, Poland, United States · 29 sites
Registry update: 21 Aug 2026
NCT07221266
Recruiting
Changes in Movement, Fitness, and Quality of Life in People With Parkinson's Disease After Different Exercise Programs
Not applicable · United States · 2 sites
Registry update: 8 May 2026
NCT05986071
Recruiting
MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)
Phase 1/2 · France · 12 sites
Registry update: 27 Mar 2026
NCT07298070
Recruiting
Functional and Aesthetic Outcomes Following Lower Lip Reconstruction
Not applicable · France · 1 site
Registry update: 9 Jun 2026
NCT07478523
Recruiting
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
Phase 2 · France · 1 site
Registry update: 30 Apr 2026
NCT07518173
Recruiting
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Phase 3 · China · 2 sites
Registry update: 4 Jun 2026
NCT07231445
Recruiting
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Phase 1 · China · 1 site
Registry update: 28 Apr 2026
NCT07518160
Recruiting
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
Phase 2 · China · 1 site
Registry update: 7 Jul 2026
NCT07569068
Recruiting
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma
Phase 2 · China · 1 site
Registry update: 6 May 2026
NCT07417488
Recruiting
GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas
Phase 1 · United States · 1 site
Registry update: 22 Oct 2026
NCT07548983
Recruiting
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
Phase 1 · United States · 1 site
Registry update: 5 Oct 2026
NCT07758569
Recruiting
Validation of the Artificial Intelligence Subsystem of the DDART Medical Device for the Automated Detection of Lesions Compatible With Glaucoma in a Random Sample of Retinal Fundus Photographs
Not applicable · Greece · 1 site
Registry update: 11 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.